Form 4: Sangamo CEO Reports Mandatory Tax Withholding Transaction

CEO Sandy Macrae disposed of 12,613 shares of Sangamo Therapeutics to satisfy mandatory tax withholding obligations related to RSU vesting.

Summary

• Reporting person Sandy Macrae, President and CEO of Sangamo Therapeutics, Inc., disposed of 12,613 shares of common stock.
• The transaction occurred on May 25, 2026, at a price of $0.1743 per share.
• The disposal was a mandatory tax withholding event related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 1,895,043 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event, as the transaction was mandatory and not a discretionary sale of shares.

Positives

• The transaction was non-discretionary and executed solely for tax compliance purposes, indicating no change in the CEO's long-term investment outlook.

Negatives

• The transaction reflects a reduction in the total number of shares held by the CEO, albeit for tax purposes.

Risks

• Continued reliance on equity-based compensation and the associated tax withholding requirements.

Future Outlook

The filing notes that 246,094 shares from the February 25, 2025 RSU grant remain to vest in 7 successive equal quarterly installments, subject to continuous service.

Industry Context

StockSavvy.ai notes that mandatory tax withholding transactions are standard administrative procedures for executives in the biotechnology sector and do not typically signal a change in corporate strategy or management confidence.

Comparison to Industry Standards

• The use of 'sell-to-cover' transactions for tax obligations is a standard practice among publicly traded biotech companies to manage executive equity compensation.
• The transaction aligns with typical corporate governance policies regarding equity incentive plans (EIP).

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax withholding event.

Next Steps

• Continued vesting of remaining RSU grants in 7 successive equal quarterly installments.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Insider Trading, Form 4, Executive Compensation, Tax Withholding